We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

116 hedge funds and large institutions have $443M invested in BioCryst Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 23

57% more call options, than puts

Call options by funds: $907K | Put options by funds: $577K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

6.96% more ownership

Funds ownership: 84.81% → 91.78% (+7%)

1% more capital invested

Capital invested by funds: $439M → $443M (+$4.9M)

3% less funds holding

Funds holding: 120 → 116 (-4)

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

Holders
116
Holders Change
-4
Holders Change %
-3.33%
% of All Funds
2.63%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
19
Increased
45
Reduced
23
Closed
23
Calls
$907K
Puts
$577K
Net Calls
+$330K
Net Calls Change
+$4.06M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$15.1M
2
DM
Deerfield Management
New York
+$10.8M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$10.7M
4
BlackRock
BlackRock
New York
+$4.81M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.52M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$6.96M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.76M
3
VMI
VHCP Management II
New York
-$3.31M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.68M
5
GTC
Ghost Tree Capital
New York
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
101
Royal Bank of Canada
Ontario, Canada
$5K -$32K -6,614 -86%
Bank of Montreal
102
Bank of Montreal
Ontario, Canada
$5K – – –
SWP
103
Stratos Wealth Partners
Ohio
$5K +$4.84K +1,000 New
SEI Investments
104
SEI Investments
Pennsylvania
$3K – – –
FMTCOCP
105
Farmers & Merchants Trust Co of Chambersburg PA
Pennsylvania
$2.46K – – –
AF
106
Allworth Financial
California
$2K – – –
LTFS
107
Ladenburg Thalmann Financial Services
Florida
$2K – – –
AG
108
Advisor Group
Arizona
$2K +$2.18K +450 New
TRCT
109
Tower Research Capital (TRC)
New York
$1K -$44.3K -9,135 -97%
Envestnet Asset Management
110
Envestnet Asset Management
Illinois
$1K – – –
KF
111
Krilogy Financial
Missouri
$1K – – –
OC
112
Oakworth Capital
Alabama
$1K – – –
PNC Financial Services Group
113
PNC Financial Services Group
Pennsylvania
$1K +$499 +103 New
STA
114
Summit Trail Advisors
New York
$1K +$828 +171 New
Citadel Advisors
115
Citadel Advisors
Florida
– -$6.76M -1,395,547 Closed
GTC
116
Ghost Tree Capital
New York
– -$2.62M -500,000 Closed
LCM
117
Laurion Capital Management
New York
– -$1.13M -216,162 Closed
PVI
118
Pura Vida Investments
New York
– -$786K -150,000 Closed
Tudor Investment Corp
119
Tudor Investment Corp
Connecticut
– -$537K -102,494 Closed
MWNA
120
Marshall Wace North America
New York
– -$424K -84,895 Closed
BCM
121
BlueCrest Capital Management
Jersey
– -$431K -82,262 Closed
Squarepoint
122
Squarepoint
New York
– -$343K -65,389 Closed
NFA
123
Nationwide Fund Advisors
Ohio
– -$230K -43,926 Closed
Susquehanna International Group
124
Susquehanna International Group
Pennsylvania
– -$189K -38,923 Closed
NPC
125
National Planning Corporation
California
– -$168K -32,000 Closed
2 3 4
5
6

BCRX Hedge Fund Activity: Q4 2017 in Review

116 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2017, worth a combined $443M — up 1.1% from $439M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of BCRX and 19 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 45 added.

The largest buyer was Great Point Partners, adding an estimated $15.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $6.96M.

  • 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2017, down from 120 in Q3 2017.
  • Funds reported $443M of BioCryst Pharmaceuticals stock for Q4 2017, up 1.1% quarter-over-quarter.
  • 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2017 and 23 closed out, a net change of -4 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2017 was Great Point Partners, an estimated $15.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2017 was Avoro Capital Advisors, an estimated $6.96M sold.

Based on aggregated 13F filings for Q4 2017.